泰恩康：CKBA乳膏玫瑰痤疮适应症获批开展Ⅱ/Ⅲ期无缝适应性临床试验
T&KT&K(SZ:301263) Zheng Quan Shi Bao Wang·2025-09-25 09:22

Core Viewpoint - The company TianKang (301263) announced that its subsidiary BoChuangYuan has received approval from the National Medical Products Administration to conduct a seamless adaptive clinical trial for CKBA cream for the indication of rosacea in phases II/III [1] Group 1 - The approval allows the company to advance its clinical research on CKBA cream, which targets rosacea [1] - The clinical trial is categorized as a seamless adaptive trial, indicating a flexible design that can adjust based on interim results [1]